Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
Androgen Replacement Therapy in Women with Hypopituitarism
This study is currently recruiting patients.
Sponsored by: | FDA Office of Orphan Products Development |
---|---|
Information provided by: | FDA Office of Orphan Products Development |
Purpose
This is a study to determine whether testosterone replacement with TheraDerm can improve bone density, mood, sex drive, thinking, and distribution of body fat and muscle mass in women with hypopituitarism.
Condition | Treatment or Intervention |
---|---|
Hypopituitarism |
Drug: TheraDerm |
MedlinePlus related topics: Pituitary Disorders
Study Type: Interventional
Study Design: Treatment, Randomized, Placebo Control, Parallel Assignment, Efficacy Study
Official Title: TheraDerm Administration in Women with Hypopituitarism
Expected Total Enrollment: 50
Study start: September 2001;
Study completion: August 2004
Patients will be randomized into 2 groups to receive testosterone replacement therapy or placebo. Group 1 will receive 2 testosterone patches and estrogen pills for 12 months. Group 2 will receive 2 placebo patches and estrogen pills for 12 months. Changes in bone density, bone metabolism markers, body composition, libido, and quality of life will be compared in the women receiving testosterone replacement therapy with that of the women receiving placebo.
Eligibility
Ages Eligible for Study: 18 Years - 50 Years, Genders Eligible for Study: Female
Criteria
Inclusion criteria:
Exclusion criteria:
Location and Contact Information
More Information
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |